Testing pirtobrutinib plus venetoclax for relapsed mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed mantle cell lymphoma from a tissue biopsy (you may be allowed even if cyclin D1 is negative if MD Anderson confirms).
- Your lymphoma has come back (relapsed) or is not responding (refractory) after prior treatment, including possible prior BTK inhibitor or anti–CD19 CAR-T (but not prior venetoclax).
- You can take oral medicines and you have at least one measurable spot of lymphoma on scans (bone marrow-only or GI-only relapse is allowed).
- You are 18 or older, and your general health ability score (ECOG) is 0–2.
- Your blood counts and organ tests are adequate, and you haven’t needed recent major transfusions or growth-factor support just to meet the minimums (with some allowances for lymphoma-related blood problems).
- You can follow safety rules for birth control during the study and for months after the last dose (and you must not be pregnant or breastfeeding).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications, pirtobrutinib and rituximab, for people newly diagnosed with low- or medium-risk mantle cell lymphoma. It aims to see if this approach is effective and safe without needing chemotherapy.
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.